- SEK43.76m
- SEK37.92m
Brief: Combigene CEO Jan Nilsson Leaves His Position, Peter Ekolind Takes Over
Brief: Combigene Says Vinnova Supports Formation Of Nordic CCRM Hub
Brief: Combigene Q4 Net Sales Down At SEK 5.3 Mln
Brief: CombiGene Enters Into Collaboration Agreement With Zyneyro
Brief: Combigene Q3 Net Sales SEK 5.2 Mln
Brief: Combigene Q2 Net Result Turns To Profit At SEK 4.5 Million
Brief: Combigene Q1 Loss After Financial Items Narrows To SEK 2.7 Mln
Brief: Combigene Signs Agreement To Evaluate Gene Therapy Candidate
Brief: Combigene Q3 Loss From Financial Items Widens To SEK 10.2 Mln
Brief: Spark Therapeutics And Combigene Enter Into Exclusive, Global Licensing Agreement For Gene Therapy Candidate CG01
Brief: Combigene And Spark Therapeutics Enter Licensing Agreement For Gene Therapy Candidate CG01
Brief: Combigene Q2 Pretax Loss Widens To SEK 15.4 Mln
Brief: CombiGene Announces Outcome In Rights Issue
Brief: Combigene Resolves On Fully Guaranteed Rights Issue Of About SEK 75 Million
Brief: CombiGene’s Lipodystrophy Project Gets EUR 882,500 In Development Funding From EU Eurostar Program
Brief: CombiGene Signs Agreement With British Neurochase
Brief: Combigene Carries Out A Directed New Issue Of Shares To Lipigon Pharmaceuticals
Brief: Combigene And Cobra Biologics Sign Agreement
Brief: Combigene Applies For Patent Protection For Vectors Developed In Lipodystrophy Project CGT2